ORICNasdaqPharmaceutical PreparationsFiscal year ends December 31
Oric Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$12.72+0.37 (+3.00%)
Close on Oct 19, 2026
- Market cap
- $1.37B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.06 (−0.47%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.37B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.60
- Dividend yield
- –
- Free cash flow yield
- -8.17%
Fundamentals
- Net income
- -$140.35M
- EPS, diluted
- -$1.35
- Free cash flow
- -$112.26M
- Book value per share
- $3.53
- Diluted shares
- 108M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Operating income
-$156.14M
Net income
-$140.35M
EPS, diluted
-$1.35
Free cash flow
-$112.26M
Reported periodTrailing twelve months